NAYA: NAYA Biosciences Corp Analyst Consensus Forecast

Symbol and logo of brand NAYA Biosciences Inc (NAYA)

This daily price chart for NAYA Biosciences (NAYA) reflects asset dynamics with a value of 6.00. NAYA Biosciences (NAYA) is recruiting leading biotechnologists and physicians to develop targeted therapies. The production cycle relies on external certified contractors in the US, which stabilizes supplies. Meanwhile, management is currently establishing an internal hierarchy, and the company's investment attractiveness depends on the outcomes of primary tests.

NAYA NAYA Biosciences Analyst Consensus Forecast (07/04/2022 - 04/28/2025)
Original product of NAYA Bio

This indicator represents the weighted average target price of the asset over a one-year horizon, aggregating professional analyst forecasts to assess fundamental growth potential. The current market consensus for NAYA Biosciences (NAYA) is 6.00, reflecting market expectations regarding the capitalization of NAYA Biosciences as it develops innovative antibodies and achieves clinical success in oncology therapies.

Competing companies

beigene.com - Broker Consensus Forecast|Analyst Consensus Forecast HALO (Halozyme)|Analyst Consensus Forecast Revolution Medicines Inc RVMD|AAPG: Consensus Target|Average Forecast Price CG Oncology Therapeutics|URGN: Analyst Consensus Forecast|bicara.com (BCAX) - Analyst Consensus Forecast|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast Y-mAbs Corp (YMAB)|Price Target Chart Aura Biosciences, Inc. AURA|CADL: Broker Consensus Forecast|Accuray - Analyst Consensus Forecast|SELLAS Life Sciences (SLS) - Consensus Target|ACTU: Analyst Consensus Forecast|Average Forecast Price Citius Oncology Inc (CTOR)|Price Target Chart TuHURA Biosciences Inc.|TARA: Fair Value Consensus|Consensus Target FATE (Fate Therapeutics)|WHWK (aadibio.com) - Fair Value Consensus|Analyst Consensus Forecast TCRX (TScan Therapeutics, Inc.)|CSBR - Consensus Target|XBIT: Consensus Target|CVM - Analyst Consensus Forecast|OS Therapies (OSTX) - Price Target Chart|Radiopharm Theranostics Ltd - Fair Value Consensus|ARTV (Artiva Biotherapeutics Inc.) - Analyst Consensus Forecast|Average Forecast Price Adlai Nortye Limited ANL|Price Target Chart Veru Inc. (VERU)|tempesttx.com - Broker Consensus Forecast|Analyst Consensus Forecast XLO (Xilio Therapeutics)|Analyst Consensus Forecast Renovaro Biosciences RENB|MURA: Consensus Target|Average Forecast Price Kairos Pharma Ltd|OKUR: Analyst Consensus Forecast|CytoMed Therapeutics Limited (GDTC) - Analyst Consensus Forecast|Consensus Target CRIS|APLM: Fair Value Consensus|Analyst Consensus Forecast THAR|Price Target Chart ADVB (advanbiomed.com)|Analyst Consensus Forecast GNPX (Genprex, Inc.)|Analyst Median Target Calidi Biotherapeutics Inc. (CLDI)|SBFM - Price Target Chart|Average Forecast Price Xenetic Biosciences|Salarius (SLRX) - Price Target Chart|PPBT - Analyst Median Target|AONC (American Oncology Network Inc) - Analyst Consensus Forecast|Consensus Target beigene.com (BGNE)|Analyst Consensus Forecast CKPT|Analyst Median Target Elevation Oncology Inc.|Analyst Consensus Forecast ICAD (iCAD)|Ikena Oncology Inc. (IKNA) - Average Forecast Price|NTBL - Price Target Chart|VIRX (Viracta Therapeutics) - Broker Consensus Forecast|MOR: Analyst Consensus Forecast|Consensus Target Ascentage Pharma Group International